Literature DB >> 28501299

Severe hypertension with renal thrombotic microangiopathy: what happened to the usual suspect?

Steven Van Laecke1, Wim Van Biesen2.   

Abstract

Patients with atypical hemolytic uremic syndrome (aHUS) and malignant hypertension can both present with concomitant hypertension and thrombotic microangiopathy (TMA), rendering policy decisions complex. Timmermans et al. report that patients with severe hypertension and renal TMA might have unrecognized aHUS with underlying complement abnormalities. Based on this, they assert that all patients presenting with severe hypertension and renal TMA should be evaluated for aHUS. It remains uncertain whether this holds equally true for patients with malignant hypertension and renal TMA.
Copyright © 2017 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28501299     DOI: 10.1016/j.kint.2017.02.025

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  9 in total

Review 1.  Thrombotic Microangiopathy and the Kidney.

Authors:  Vicky Brocklebank; Katrina M Wood; David Kavanagh
Journal:  Clin J Am Soc Nephrol       Date:  2017-10-17       Impact factor: 8.237

2.  Clinical characteristics and outcomes of a patient population with atypical hemolytic uremic syndrome and malignant hypertension: analysis from the Global aHUS registry.

Authors:  Jean-Michel Halimi; Imad Al-Dakkak; Katerina Anokhina; Gianluigi Ardissino; Christoph Licht; Wai H Lim; Annick Massart; Franz Schaefer; Johan Vande Walle; Eric Rondeau
Journal:  J Nephrol       Date:  2022-09-24       Impact factor: 4.393

3.  Genetic testing of complement and coagulation pathways in patients with severe hypertension and renal microangiopathy.

Authors:  Christopher P Larsen; Jon D Wilson; Alejandro Best-Rocha; Marjorie L Beggs; Randolph A Hennigar
Journal:  Mod Pathol       Date:  2017-11-17       Impact factor: 7.842

4.  Deterioration in Clinical Status Is Not Enough to Suspend Eculizumab: A Genetic Complement-Mediated Atypical Hemolytic Uremic Syndrome Case Report.

Authors:  Luca Calvaruso; Alessandro Naticchia; Pietro Manuel Ferraro; Gisella Vischini; Stefano Costanzi
Journal:  Case Rep Nephrol       Date:  2019-07-09

5.  Circulating microRNAs May Serve as Biomarkers for Hypertensive Emergency End-Organ Injuries and Address Underlying Pathways in an Animal Model.

Authors:  Knut Asbjørn Rise Langlo; Gustavo Jose Justo Silva; Tina Syvertsen Overrein; Volker Adams; Ulrik Wisløff; Håvard Dalen; Natale Rolim; Stein Ivar Hallan
Journal:  Front Cardiovasc Med       Date:  2021-02-12

6.  Protease-Activated Receptor 1 Contributes to Microcirculation Failure and Tubular Damage in Renal Ischemia-Reperfusion Injury in Mice.

Authors:  Yu Guan; Daisuke Nakano; Lei Li; Haofeng Zheng; Akira Nishiyama; Ye Tian; Lei Zhang
Journal:  Biomed Res Int       Date:  2021-02-23       Impact factor: 3.411

Review 7.  ACE-2 down-regulation may act as a transient molecular disease causing RAAS dysregulation and tissue damage in the microcirculatory environment among COVID-19 patients.

Authors:  Simone Gusmão Ramos; Bruna Amanda da Cruz Rattis; Giulia Ottaviani; Mara Rubia Nunes Celes; Eliane Pedra Dias
Journal:  Am J Pathol       Date:  2021-05-05       Impact factor: 4.307

8.  Genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and C3 glomerulopathy.

Authors:  Ludwig Haydock; Alexandre P Garneau; Laurence Tremblay; Hai-Yun Yen; Hanlin Gao; Raphaël Harrisson; Paul Isenring
Journal:  J Mol Med (Berl)       Date:  2021-10-29       Impact factor: 4.599

9.  Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.

Authors:  Vicky Brocklebank; David Kavanagh
Journal:  Clin Kidney J       Date:  2017-05-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.